Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban-Reference-Cited by-同舟云学术

Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban

Published:2013-05-14 Issue:6 Volume:102 Page:399-412
ISSN:1861-0684
Container-title:Clinical Research in Cardiology
language:en
Short-container-title:Clin Res Cardiol

Author:

Steiner T.,Böhm M.,Dichgans M.,Diener H.-C.,Ell C.,Endres M.,Epple C.,Grond M.,Laufs U.,Nickenig G.,Riess H.,Röther J.,Schellinger P. D.,Spannagl M.,Veltkamp R.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00392-013-0560-7.pdf

Reference72 articles.

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. doi: 10.1056/NEJMoa0905561

2. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L (2010) Newly identified events in the RE-LY trial. N Engl J Med 363(19):1875–1876. doi: 10.1056/NEJMc1007378

3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992. doi: 10.1056/NEJMoa1107039

4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891. doi: 10.1056/NEJMoa1009638

5. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806–817. doi: 10.1056/NEJMoa1007432

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing mortality and safety of IV thrombolysis in ischemic stroke patients on direct oral anticoagulants (DOACs): A systematic review and meta-analysis;Clinical Neurology and Neurosurgery;2024-11

2. Acute ischemic stroke and measurement of apixaban and rivaroxaban: an observational cohort implementation study;Research and Practice in Thrombosis and Haemostasis;2024-01

3. Cribado virtual y análisis de complejos enzima-ligando para el factor Xa (FXa) en la cascada de la coagulación humana;Bionatura;2023-12-15

4. Poor Correlation of Rivaroxaban Concentration with the Routine Coagulation Screening Test in Chinese Patients with Atrial Fibrillation;Journal of Clinical Pharmacy and Therapeutics;2023-10-31

5. Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study;CPT: Pharmacometrics & Systems Pharmacology;2023-09-18